肝硬化门静脉血栓防治的新靶点  

New targets for the prevention and treatment of cirrhotic portal vein thrombosis

作　　者：王宇威 丁惠国 Wang Yuwei;Ding Huiguo(Department of Hepatology and Gastroenterology,You'an Hospital,Capital Medical University,Beijing 100000,China)

机构地区：[1]首都医科大学附属北京佑安医院肝病消化中心,北京100000

出　　处：《中华肝脏病杂志》2024年第6期484-488,共5页Chinese Journal of Hepatology

基　　金：首都卫生发展科研专项项目(2022-1-2181);首都特色诊疗技术研究及转化应用重点专项(Z221100007422002)。

摘　　要：门静脉血栓(PVT)分为肝硬化性PVT和非肝硬化性PVT。PVT发病率在肝硬化不同临床阶段差别较大,总体发病率约为13.92%,而肝硬化脾切除术后PVT患病率高达60%。肝硬化性PVT的发病机制尚不明确,但Janus激酶/信号转导与转录激活子信号通路活化、血管性血友病因子表达增加、肠道菌群及其代谢产物三甲胺-N-氧化物在肝硬化血管内皮细胞损伤、PVT形成中具有重要作用,可能是肝硬化性PVT防治的新靶点。Portal vein thrombosis(PVT)is divided into cirrhotic and non-cirrhotic PVTs.The incidence rate of PVT varies greatly among different clinical stages of cirrhosis,with an overall incidence rate of about 13.92%,and the prevalence of cirrhotic PVT following splenectomy is as high as 60%.The pathogenesis of cirrhotic PVT is still unclear.However,the activation of Janus kinase/signal transduction and activator transcription signaling pathways,the rise in the expression of von Willebrand factor,and the gut microbiota along with its metabolite trimethylamine-N-oxide play an important role in the injury of vascular endothelial cells and the formation of PVT in cirrhosis.Therefore,these could be a new target for cirrhotic PVT prevention and treatment.

关 键 词：肝硬化 门静脉血栓 治疗 危险因素 肠道菌群 预防 靶点 

分 类 号：R575.2[医药卫生—消化系统]